Regeneron Pharmaceuticals Inc. buy Guggenheim
Summary
This prediction is currently active. Since the start of the prediction for Regeneron Pharmaceuticals Inc. the price has only changed by 0.45%. This prediction currently runs until 19.07.25. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w |
---|---|
Regeneron Pharmaceuticals Inc. | 0.45% |
iShares Core DAX® | -3.033% |
iShares Nasdaq 100 | -3.554% |
iShares Nikkei 225® | -3.938% |
iShares S&P 500 | -1.517% |
Comments by Guggenheim for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren